KRTX News and Press, Karuna Therapeutics Inc. From 12/06/21

Although the Healthcare sector is having a positive year in absolute terms, that isn't the case in relative terms. Biotech stocks are having a difficult year, in spite of many of those trading at dirt-cheap valuations that don't even reflect the cash they have in-hand. It's very l...

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced the appointment of Charmaine Lykins as chief commercial officer, eff...

Zai will have greater China rights to two Blueprint next-gen EGFR candidates aimed at non-small cell lung cancer (NSCLC), which Blueprint says have first-in-class potential. Earlier this year, I-Mab started a pivotal China Phase III trial of eftansomatropin alfa as a weekly treatment ...

Shares of clinical-stage biotech Karuna Therapeutics (NASDAQ: KRTX) are down by a hefty 10% through the first four days of trading this week, according to data from S&P Global Market Intelligence . Karuna's shares started to slide earlier this week after the company announce...

Karuna Therapeutics (NASDAQ:KRTX) has entered into an exclusive license agreement with Zai Lab (NASDAQ:ZLAB) for the development, production, and commercialization of KarXT (xanomeline-trospium) in Greater China. KarXT is currently undergoing studies as a potential treatment for schizoph...

Zai Lab obtains exclusive rights to develop and commercialize KarXT in Greater China Karuna to receive upfront cash payment of $35 million, up to $152 million in potential near- and long-term development and commercial milestones and other payments, and low-double-digit to hig...

Zai Lab obtains exclusive rights to develop and commercialize KarXT in Greater China Karuna to receive upfront cash payment of $35 million, up to $152 million in potential near- and long-term development and commercial milestones and other payments, and low-double-digit to hig...

Karuna Therapeutics (NASDAQ:KRTX): Q3 GAAP EPS of -$1.72 misses by $0.27. For further details see: Karuna Therapeutics EPS misses by $0.27

Topline data from the Phase 3 EMERGENT-2 and EMERGENT-3 trials expected in mid-2022 and in the second half of 2022, respectively On track to initiate the Phase 3 ARISE trial evaluating KarXT in adults with schizophrenia who inadequately respond to current standard of care ...

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that senior management will participate in a fireside chat at the 20...